Sutureless valves have recently been developed to streamline surgical aortic valve replacement (SAVR) procedures, with the hope that shorter operations lead to better outcomes. But a new study in the Journal of the American College of Cardiology suggests quicker is not always better.

Bioprosthetic heart valves used in surgical aortic valve replacement (SAVR) procedures in the early 2000s demonstrated “satisfactory” durability, according to a single-center study published in the Journal of the American College of Cardiology.

A high dose of oral ibuprofen appeared to be the best option for closing patent ductus arteriosus (PDA) in a meta-analysis of 4,802 preterm infants, researchers reported in JAMA.

Edwards Lifesciences notched a victory in its ongoing dispute with Boston Scientific concerning transcatheter aortic valve replacement (TAVR) patents.

Occluder devices to combat congenital structural heart defects designed by the indigenous Aymara women suggest “excellent” clinical outcomes and have been approved by regulatory agencies in Canada, South America and the European Union.

Edwards Lifesciences Corporation today announced that enrollment is complete in the computed tomography (CT) imaging sub-study within the PARTNER 3 trial of the SAPIEN 3 valve.

Avid Star Wars fan Austin Eggleston, a 15-year-old heart transplant hopeful, finally received the news he was going to receive a new heart from Chewbacca, the big, furry character from a galaxy far, far away. 

ABBOTT PARK, Ill., March 19, 2018 — Abbott today announced that the Ministry of Health Labour and Welfare (MHLW) in Japan granted national reimbursement for the company's MitraClip therapy to treat people with mitral regurgitation, a serious, progressive heart disease in which the mitral valve does not close properly, allowing blood to flow backward into the heart.